Hikma launches US ritonavir exclusively

  
Generate a summary of this article
Listen to this article
Beta

Hikma has through its US West-Ward Pharmaceuticals subsidiary launched “the first AB-rated generic” version of AbbVie’s Norvir (ritonavir) 100mg tablets. According to the US Food and Drug Administration (FDA) approval letter, the Jordanian firm was the “first applicant to submit a substantially complete abbreviated new drug application (ANDA) for ritonavir 100mg [tablets], with one or more paragraph IV certifications”. Therefore, the agency noted, Hikma was eligible for 180-days of exclusivity.

Hikma has through its US West-Ward Pharmaceuticals subsidiary launched “the first AB-rated generic” version of AbbVie’s Norvir (ritonavir) 100mg tablets. According to the US Food and Drug Administration (FDA) approval letter, the Jordanian firm was the “first applicant to submit a substantially complete abbreviated new drug application (ANDA) for ritonavir 100mg [tablets], with one or more paragraph IV certifications”. Therefore, the agency noted, Hikma was eligible for 180-days of exclusivity.

“We will be launching ritonavir with additional patient support and co-pay assistance to ensure more people are able to access...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.